PharmaCyte Biotech will do a 1-for-19 reverse stock split on November 12, 2026, to raise its share price.

Nov 13, 2026, 4:31 PM ETNew sharesRead the original at SEC EDGAR

Neutral

PharmaCyte combined every 19 shares into 1, aiming to meet Nasdaq’s minimum price rule. The filing does not confirm that it has met the rule, and authorized share count stayed unchanged, so the change alone does not alter its business outlook.

PMCB · PharmaCyte Biotech, Inc.

AI read · Neutral

The AI's read

The change affects share counts and the quoted share price, not what PharmaCyte owns or sells. The filing says the company aims to meet Nasdaq’s minimum price rule, but does not say it has done so. Authorized share count stayed unchanged, so future share issuance remains possible.

Get alerts for PMCB

Follow PharmaCyte Biotech, Inc. (PMCB) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for PMCB

Free on the App Store and Google Play, or on the web.